Linking Gene Mutations to Clinical Outcomes and Response to Therapy in Clear-cell Renal Cell Carcinoma: Ready for Prime Time?

Affiliations

¹ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Medical Oncology, Pitie-Salpêtrière Hospital, University Pierre and Marie Curie, Paris, France.
³ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ntannir@mdanderson.org.

Editorial

Pavlos Msaouel et al. Eur Urol. 2017 Mar.

. 2017 Mar;71(3):415-416.

doi: 10.1016/j.eururo.2016.10.034. Epub 2016 Nov 2.

¹ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Medical Oncology, Pitie-Salpêtrière Hospital, University Pierre and Marie Curie, Paris, France.
³ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ntannir@mdanderson.org.

No abstract available

Comment on

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
Hsieh JJ, Chen D, Wang PI, Marker M, Redzematovic A, Chen YB, Selcuklu SD, Weinhold N, Bouvier N, Huberman KH, Bhanot U, Chevinsky MS, Patel P, Pinciroli P, Won HH, You D, Viale A, Lee W, Hakimi AA, Berger MF, Socci ND, Cheng EH, Knox J, Voss MH, Voi M, Motzer RJ. Hsieh JJ, et al. Eur Urol. 2017 Mar;71(3):405-414. doi: 10.1016/j.eururo.2016.10.007. Epub 2016 Oct 15. Eur Urol. 2017. PMID: 27751729 Free PMC article.

1. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature, 499 (2013), pp. 43–49. - PMC - PubMed
1. Kaelin WG Jr. The von Hippel-Lindau tumour suppressor protein: O₂ sensing and cancer. Nat Rev Cancer, 8 (2008), pp. 865–873. - PubMed
1. Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users’ guide to the medical literature. JAMA, 311 (2014), pp. 405–411. - PubMed
1. Hsieh JJ, Chen D, Wang PI, et al. Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma Eur Urol, 71 (2017), pp. 405–414. - PMC - PubMed
1. Larkin J, Goh XY, Vetter M, Pickering L, Swanton C. Epigenetic regulation in RCC: opportunities for therapeutic intervention? Nat Rev Urol, 9 (2012), pp. 147–155. - PubMed